Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report by Cerri, Stefania et al.
CASE REPORT Open Access
Occurrence of idiopathic pulmonary fibrosis
during immunosuppressive treatment: a
case report
Stefania Cerri1, Giacomo Sgalla2,3, Luca Richeldi2,3 and Fabrizio Luppi1*
Abstract
Background: Immunosuppressive therapy has been—until the recent release of new guidelines on diagnosis and
management—the recommended treatment for idiopathic pulmonary fibrosis. However, its efficacy in patients with
idiopathic pulmonary fibrosis has always been a matter of debate.
Case presentation: We report the occurrence of idiopathic pulmonary fibrosis in a white man receiving chronic
immunosuppressive treatment following a heart transplant.
Conclusions: This case report suggests that the immune mechanisms targeted by azathioprine and cyclosporine
do not play a role in the pathogenesis of idiopathic pulmonary fibrosis.
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Background
Idiopathic pulmonary fibrosis (IPF) is a devastating lung
disorder with a median survival of 3.5 years from
diagnosis [1]. Until the recent release of the American
Thoracic Society/European Respiratory Society/Japanese
Respiratory Society/Latin American Thoracic Association
guidelines [2], the standard of care for IPF consisted of
corticosteroids and azathioprine in combination, although
clinical practice suggests that immunosuppression does
not impact the survival of patients with IPF. In addition,
the authors of an interim analysis of a large, multicenter,
placebo-controlled study [3] warned that a treatment regi-
men including prednisone and azathioprine is harmful for
patients with IPF. Indeed, in that study sponsored by the
National Heart, Lung, and Blood Institute, patients
with IPF receiving a triple therapy with prednisone,
azathioprine, and N-acetylcysteine showed higher
mortality (11 %) than those receiving placebo (1 %). In
this case report, we discuss the occurrence of IPF in a
patient receiving chronic immunosuppressive treat-
ment following a heart transplant.
Case presentation
Our patient was a 75-year-old white man who was a
former smoker (20 pack-years) with no relevant family
history of lung disease. He had been a farmer until the age
of 40 years. At the age of 42 years, he had an acute myo-
cardial infarction, which led to the development of
chronic heart failure with recurrent episodes of pulmonary
edema. His medications included acetylsalicylic acid (150
mg/day) and amiloride/hydrochlorothiazide (5/50 mg/day,
respectively). He had never received antiarrhythmic drugs,
including amiodarone. Due to worsening clinical condi-
tions, at the age of 54 years he was included on a heart
transplant list and after 2 years on the list he underwent a
heart transplant. At that time, his chest x-ray and lung
function test results, including forced vital capacity (FVC)
and diffusing capacity of the lungs for carbon monoxide
(DLCO), were normal.
The patient, who was already being treated with felodi-
pine (5 mg/day) and atorvastatin (5 mg/day), was initially
started on azathioprine (50 mg twice daily), cyclosporine
(100 mg twice daily) and prednisone, with the first two
drugs being maintained in the long-term treatment. At the
age of 65 years, following a chest trauma, he underwent
chest radiography, which revealed the presence of bilateral
reticulonodular abnormalities predominant in the lower
lobes. Chest high-resolution computed tomography
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confirmed the presence of bilateral reticular abnormalities
with minimum honeycombing in the periphery of both
lower lobes. Chest auscultation revealed bibasal pulmonary
“velcro” crackles. Lung function tests showed a mild re-
strictive ventilatory defect: FVC 73 % of predicted, forced
expiratory volume in 1 second 75 % of predicted, total lung
capacity 67 % of predicted, and DLCO 60 % of predicted.
The patient was completely asymptomatic. Bronchoalveolar
lavage (BAL) cytology showed a slight lymphocytosis with
prevalence of CD4+ T lymphocytes and a CD4/CD8 ratio
of 3.6. Direct stains and cultures for bacteria, fungi, and
mycobacteria on BAL samples were negative. Serum and
BAL precipitins were negative.
To confirm the suspicion of IPF, an open lung biopsy
with sampling in the right lower and middle lobes was
performed. The histological pattern was consistent with
usual interstitial pneumonia (UIP), thus providing, after
exclusion of secondary causes and in the absence of ele-
ments for relevant professional and/or environmental
exposures, the definite diagnosis of IPF was made 10
Fig. 1 Timeline of the patient’s clinical history. HRCT high-resolution computed tomography, IPF idiopathic pulmonary fibrosis
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years after initiation of immunosuppressive therapy. While
continuing immunosuppressive treatment, the patient’s
clinical conditions progressively worsened (FVC 44 % pre-
dicted and DLCO 4 % predicted), as expected in IPF. He
died as a result of respiratory failure 5 years after receiving
his diagnosis of IPF (Fig. 1).
Discussion
Immunosuppression has long been the mainstream IPF
treatment, despite scarce evidence of an impact on the nat-
ural history of the disease [4]. In fact, according to recent
advances in IPF pathobiology, inflammation plays a min-
or—if any—role in the development of the disease [5, 6].
Azathioprine, an antimetabolite that exerts its im-
munosuppressive effects through the block of several
T-cell functions, the inhibition of antibody synthesis,
and the reduction of circulating monocytes and granu-
locytes [7], was, in combination with corticosteroids,
the recommended treatment for IPF until the recent
release of evidence-based guidelines on IPF. Now-
adays, the mainstream IPF treatment is based on drugs
with antifibrotic activity, such as pirfenidone and nin-
tedanib, which have shown meaningful slowing of the
rate of disease progression as measured by the rate of
FVC decline [8, 9].
We report the occurrence of IPF in a patient on long-
term azathioprine treatment in whom other known
causes of pulmonary fibrosis with a histological pattern
of UIP were excluded. In fact, although the patient
worked as a farmer until the age of 40 years, a diagnosis
of chronic hypersensitivity pneumonitis (HP) in our pa-
tient is unlikely. Particularly, histology showed a definite
UIP pattern without any of the “ancillary findings” that
are usually observed in patients with chronic HP, such as
granulomas, eosinophils, and “bridging fibrosis.” Fur-
thermore, his serum and BAL precipitins were negative.
As far as exclusion of possible drug-induced interstitial
lung disease (ILD), we acknowledge that statin use may
perhaps increase the risk of developing radiographic evi-
dence of ILD, including findings characteristic of pulmon-
ary fibrosis [10]; however, the occurrence of statin-induced
ILD with a definite UIP pattern is not definitively estab-
lished and is unlikely. Furthermore, there are no reports on
atorvastatin in this clinical setting.
The occurrence of pulmonary interstitial pneumonitis
during azathioprine treatment is well described [11–14].
However, azathioprine-induced pulmonary toxicity in
the form of interstitial pneumonitis is commonly an
acute or subacute event occurring early after treatment
is initiated (ranging from 6 weeks to 1 year). Bedrossian
and coworkers [11] reported the presence of a UIP-like
pattern on lung biopsies of five patients taking azathio-
prine after kidney transplant, within 1 year after initi-
ation of treatment. Three of the patients died due to
acute respiratory distress syndrome a few days after lung
biopsy, one patient died as a result of disseminated As-
pergillus infection 30 days after biopsy, and one patient
survived and recovered after azathioprine discontinu-
ation and institution of cyclophosphamide therapy.
Therefore, to the best of our knowledge, no sure cases
of IPF fulfilling the currently accepted diagnostic criteria
for the disease have been described during treatment
with azathioprine.
Conclusions
Although we cannot exclude the presence of early subclin-
ical IPF at the time of heart transplant, our patient’s case
provides indirect evidence that the mechanisms affected by
conventional immunosuppressive therapies do not play a
major role in the pathogenesis of IPF. Moreover, we cannot
exclude that in this patient immunosuppressive treatment
accelerated or worsened lung function deterioration in line
with the data provided by the Prednisone, Azathioprine,
and N-acetylcysteine in Patients with IPF study [3].
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